Literature DB >> 18301733

PHENETIC COMPARISON OF SEVEN Echinacea SPECIES BASED ON IMMUNOMODULATORY CHARACTERISTICS.

David S Senchina1, Lex E Flagel, Jonathan F Wendel, Marian L Kohut.   

Abstract

The purpose of the present investigation was to compare similarities and differences in immune response among Echinacea species, which are commonly used to treat upper respiratory infections. The investigation involved two components: acquisition of immunomodulatory data reported here for the first time, and combined phenetic analysis of these data along with previous reports. Experimental data were obtained by stimulating human PBMC in vitro with extracts from Echinacea spp. and assaying production of three cytokines (interleukin-1β [IL-1β], interleukin-2 [IL-2], and tumor necrosis factor-α [TNF-α]). Phenetic analyses were employed to compare responses across the entire data set, including UPGMA (Unweighted Pair Group Method with Arithmetic Mean) and neighbor-joining methods. In the immune experiments conducted for this investigation, E. angustifolia, E. paradoxa, E. purpurea, E. simulata, and E. tennesseensis extracts significantly augmented IL-1 β and TNF-α production, whereas no extracts significantly modulated IL-2. All phenetic methods produced similar dendrograms, revealing two species pairs (E. angustifolia + E. simulata and E. pallida + E.sanguinea) where both species cluster tightly and have similar immune-response profiles. These two species-pairs are maximally dissimilar from each other. The remaining species (E. paradoxa, E. purpurea, and E. tennesseensis) occupy intermediate positions in the dendrogram. Our results suggest that Echinacea spp. act heterogeneously on immune function. The utility of these data for science and industry is discussed.

Entities:  

Year:  2006        PMID: 18301733      PMCID: PMC2254517          DOI: 10.1663/0013-0001(2006)60[205:pcoses]2.0.co;2

Source DB:  PubMed          Journal:  Econ Bot        ISSN: 0013-0001            Impact factor:   1.731


  26 in total

1.  Regulation of human immune gene expression as influenced by a commercial blended Echinacea product: preliminary studies.

Authors:  R K Randolph; K Gellenbeck; K Stonebrook; E Brovelli; Y Qian; D Bankaitis-Davis; J Cheronis
Journal:  Exp Biol Med (Maywood)       Date:  2003-10

Review 2.  Treatment of the common cold with echinacea: a structured review.

Authors:  Thomas J Caruso; Jack M Gwaltney
Journal:  Clin Infect Dis       Date:  2005-02-18       Impact factor: 9.079

3.  Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea.

Authors:  B Luettig; C Steinmüller; G E Gifford; H Wagner; M L Lohmann-Matthes
Journal:  J Natl Cancer Inst       Date:  1989-05-03       Impact factor: 13.506

4.  An evaluation of Echinacea angustifolia in experimental rhinovirus infections.

Authors:  Ronald B Turner; Rudolf Bauer; Karin Woelkart; Thomas C Hulsey; J David Gangemi
Journal:  N Engl J Med       Date:  2005-07-28       Impact factor: 91.245

Review 5.  Interleukin 1: an immunological perspective.

Authors:  S K Durum; J A Schmidt; J J Oppenheim
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

6.  A proprietary extract from the echinacea plant (Echinacea purpurea) enhances systemic immune response during a common cold.

Authors:  Vinti Goel; Ray Lovlin; Chuck Chang; Jan V Slama; Richard Barton; Roland Gahler; R Bauer; L Goonewardene; Tapan K Basu
Journal:  Phytother Res       Date:  2005-08       Impact factor: 5.878

7.  Changes in immunomodulatory properties of Echinacea spp. root infusions and tinctures stored at 4 degrees C for four days.

Authors:  David S Senchina; Dustin A McCann; Jessica M Asp; Jack A Johnson; Joan E Cunnick; Mark S Kaiser; Marian L Kohut
Journal:  Clin Chim Acta       Date:  2005-05       Impact factor: 3.786

Review 8.  Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties.

Authors:  Joanne Barnes; Linda A Anderson; Simon Gibbons; J David Phillipson
Journal:  J Pharm Pharmacol       Date:  2005-08       Impact factor: 3.765

9.  Antiviral activity of characterized extracts from echinacea spp. (Heliantheae: Asteraceae) against herpes simplex virus (HSV-I).

Authors:  S E Binns; J Hudson; S Merali; J T Arnason
Journal:  Planta Med       Date:  2002-09       Impact factor: 3.352

10.  Oral administration of freshly expressed juice of Echinacea purpurea herbs fail to stimulate the nonspecific immune response in healthy young men: results of a double-blind, placebo-controlled crossover study.

Authors:  Eveline Schwarz; Joerg Metzler; Jens P Diedrich; Johannes Freudenstein; Christiane Bode; J Christian Bode
Journal:  J Immunother       Date:  2002 Sep-Oct       Impact factor: 4.456

View more
  4 in total

1.  Echinacea tennesseensis ethanol tinctures harbor cytokine- and proliferation-enhancing capacities.

Authors:  David S Senchina; Dustin A McCann; Gina N Flinn; Lankun Wu; Zili Zhai; Joan E Cunnick; Eve S Wurtele; Marian L Kohut
Journal:  Cytokine       Date:  2009-03-14       Impact factor: 3.861

2.  Metabolic profiling of echinacea genotypes and a test of alternative taxonomic treatments.

Authors:  Lankun Wu; Philip M Dixon; Basil J Nikolau; George A Kraus; Mark P Widrlechner; Eve Syrkin Wurtele
Journal:  Planta Med       Date:  2008-12-19       Impact factor: 3.352

3.  A quantitative synthesis of the medicinal ethnobotany of the Malinké of Mali and the Asháninka of Peru, with a new theoretical framework.

Authors:  Nathaniel Bletter
Journal:  J Ethnobiol Ethnomed       Date:  2007-12-05       Impact factor: 2.733

4.  A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19?

Authors:  Monique Aucoin; Valentina Cardozo; Meagan D McLaren; Anna Garber; Daniella Remy; Joy Baker; Adam Gratton; Mohammed Ali Kala; Sasha Monteiro; Cara Warder; Alessandra Perciballi; Kieran Cooley
Journal:  Metabol Open       Date:  2021-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.